Universal flu vax for 50-64 year-olds cost effective in Australia
- PDF / 143,093 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 48 Downloads / 216 Views
) per: Case of ILI averted Hospitalisation averted Death averted Life-year saved QALY gained
Governmental
Societal
Healthcare payer
7589 20 228
2824 7527
3017 8041
264 992 17 289 22 408
98 602 6433 8338
105 343 6873 8908
Probabilistic sensitivity analyses revealed that, based on a maximum cost-effectiveness threshold of $A50 000/QALY gained, > 99% of simulations from all perspectives were cost-effective in this age group. The risk of death due to influenza and the proportion of patients at high-risk (including patients with chronic diseases and those with weakened immune systems) were the most influential factors in these analyses. * see PharmacoEconomics and Outcomes News 487 p5; 801018655 and PharmacoEconomics and Outcomes News 499 p3; 801017490 ** CSL Biotherapies, Sanofi Pasteur and Solvay Pharmaceuticals provided funding for this project. Newall AT, et al. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine 26: 2142-2153, No. 17, 801102205 16 Apr 2008
1173-5503/10/0551-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 19 Apr 2008 No. 551
1
Data Loading...
